Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
340B overhaul bill draws sharply divided testimony on transparency and costs
Summary
Second Substitute Senate Bill 59 81 would bar manufacturers or third parties from restricting 340B drug acquisition or conditioning access on data, require hospital and manufacturer reporting, and authorize fines; supporters say it protects the safety net, opponents warn of higher employer/taxpayer costs and litigation risk.
Committee staff summarized Second Substitute Senate Bill 59 81 as a measure to protect covered entities' access to 340B drug discounts, to require annual reporting from covered hospitals and manufacturers about costs, discounts and use of savings, and to prohibit manufacturers or agents from denying acquisition or requiring data submissions as a condition of participation.
Supporters — community health centers, rural hospitals and patient advocates — argued the 340B program funds…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
